An Analysis on the Clinical Features of Maintenance Hemodialysis Patients with Coronavirus Disease 2019: A Single Center Study

Li Cheng¹, Yonglong Min¹, Can Tu¹, Dongdong Mao¹, Yuanyuan Yang², Yuting Song², Sheng Wan¹, Yanqiong Ding¹, Fei Xiong¹
¹Department of Nephrology, Wuhan No. 1 Hospital, Wuhan Hemodialysis Quality Control Center, ²The First Clinical College of Hubei University of Traditional Chinese Medicine, Wuhan, China

Abstract

Background and Objectives: Patients on maintenance hemodialysis (MHD) are at high risk for coronavirus disease 2019 (COVID-19). However, patients undergoing MHD who are infected with COVID-19 are not fully studied. The objective of this study is to describe the characteristics of patients with COVID-19 undergoing MHD and provide a basis for the recognition and prevention of COVID-19 infection. Materials and Methods: Patients undergoing MHD were assigned into the normal group (537 cases), diagnosed group (66 cases), and suspected group (24 cases). General data, clinical symptoms, hemodialysis indicators, and laboratory indicators were collected and compared. Results: A total of 627 patients undergoing MHD were evaluated. The prevalence of COVID-19 was 10.53% (66/627), mortality was 18.18% (12/66), and death rate was 1.91% (12/627). In addition, 26% of patients were asymptomatic. Cough was the most common symptom (36%), followed by fatigue (16%), dyspnea (16%), and fever (13%). Ultrafiltration volume, ultrafiltration rate, and the duration of weekly dialysis in the diagnosed group were significantly lower than those in the other two groups. Moreover, neutrophil ratio and neutrophil, monocyte, and total carbon dioxide levels in the diagnosed group were significantly higher than those in the normal group, and the lymphocyte ratio was considerably lower than in the normal group. Sixty-five of the suspected and diagnosed patients had positive pulmonary CT findings. Conclusion: Compared with the general population, patients on hemodialysis have a significantly higher risk of contracting COVID-19 and postinfection mortality. Moreover, most patients undergoing hemodialysis have no obvious clinical symptoms after infection with COVID-19 but only have pulmonary changes which make it particularly important to screen and manage patients undergoing hemodialysis on outpatient basis.

Key words: Clinical characteristics, hemodialysis, novel coronavirus

INTRODUCTION

In early December 2019, the first case of pneumonia of unknown source occurred in Wuhan, Hubei Province. Soon after, it was identified that the infection was caused by the novel coronavirus (2019-nCoV). As of April 1, 2020, the virus has infected more than 877,000 people and caused the death of more than 43,000 people across six continents. Its primary routes of transmission are respiratory droplets and contact transmission. The clinical manifestations include fever, fatigue, and dry cough, which gradually develop into dyspnea.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Cheng L, Min Y, Tu C, Mao D, Yang Y, Song Y et al. An analysis on the clinical features of maintenance hemodialysis patients with coronavirus disease 2019: A single center study. Integr Med Nephrol Androl 2022;9:6.
Most patients have a good prognosis, yet, in certain cases, especially in the elderly population, the virus may cause acute respiratory distress syndrome, septic shock, or even death.

Patients undergoing hemodialysis generally have hypoimmunity. Their frequent visits to and from hospitals may increase their exposure to infections. Even though they remain in hemodialysis rooms with a relatively closed environment and concentrated staff, their condition is often accompanied by various complications, such as cardiovascular and cerebrovascular diseases and diabetes, making them a high-risk group for infection. The purpose of this study is to describe the characteristics of coronavirus disease 2019 (COVID-19) infection in patients undergoing maintenance hemodialysis (MHD) and to provide evidence for the recognition and prevention of COVID-19 infection.

MATERIALS AND METHODS

Study participants
Patients undergoing MHD in the Blood Purification Center of Wuhan No. 1 Hospital from December 30, 2019, to February 20, 2020, were enrolled in this study. This study was approved by the Ethics Committee of Wuhan First Hospital ([2020] No. 8) (Trial Registration: ChiCTR, ChiCTR2000030719). On March 12, 2020, registered, http://www.chictr.org.cn/showproj.aspx?Proj=50,867). This study followed the guidelines of the Declaration of Helsinki and the consent was obtained from all parents.

Data collection
General data, including sex, age, clinical symptoms, primary disease, hemodialysis indicators (including hemodialysis years, duration of hemodialysis, vascular access type, dry weight, ultrafiltration volume, ultrafiltration rate, dehydration ratio, systolic blood pressure, and diastolic blood pressure) and laboratory indicators (white blood cell [WBC] count, red blood cell [RBC] count, hemoglobin [Hb] level, platelet [PLT] count, neutrophil ratio [N%], neutrophil count [N#], lymphocyte ratio [L%], lymphocyte count [L#], monocyte percentage [M%], monocyte count [M#], erythrocyte sedimentation rate [ESR], and glutamic pyruvic transaminase [GPT], glutamic oxaloacetic transaminase [GOT], total protein [TP], albumin [ALB], γ-glutamyl transpeptidase [γ-GT], urea nitrogen [BUN], creatinine [Cr], total carbon dioxide [TCO₂], uric acid [UA], kalium [K], calcium [Ca], phosphorus [P], serum ferritin [SF], parathyroid hormone [PTH], C-reactive protein [CRP], procalcitonin [PCT], and lactate dehydrogenase [LDH] levels) were collected and compared.

Diagnostic criteria
Patients undergoing MHD were defined as patients who have undergone hemodialysis for at least 3 months. Suspected and confirmed COVID-19 patients were diagnosed according to COVID-19 Diagnosis and Treatment Protocol (Trial Version 6) jointly released by the NHC and the National Administration of Traditional Chinese Medicine. In short, the suspected cases of COVID-19 were defined as ones with epidemiological history and clinical symptoms, including fever, respiratory symptoms, radiological features of viral pneumonia, normal or reduced total WBC count, and reduced L#. The confirmed COVID-19 cases were defined as having positive results from high-throughput sequencing or real-time reverse transcriptase chain reaction (RT-PCR).

Statistical analysis
SPSS 22.0 software (IBM, Armonk, NY, USA) was used for the data analysis. Measurement data with normal distribution were expressed as mean ± standard deviation and those with skewed distribution were expressed as median and interquartile spacing, i.e., M (P25, P75). Enumeration data were expressed as n (%). The measurement data with normal distribution were compared by ANOVA, and those with skewed distribution were analyzed by Mann–Whitney U-test. Kruskal–Wallis test was used between multiple groups, and enumeration data were analyzed by the χ² test. P < 0.05 was considered to be statistically significant.

RESULTS

General characteristics
Up to February 20, 2020, there were 627 patients undergoing MHD in the hemodialysis center of the Wuhan No. 1 Hospital; 66 were diagnosed with COVID-19, 24 were suspected with COVID-19 infection, and 12 died due to COVID-19 infection. The mortality rate after infection with COVID-19 was 18.18%, and the overall mortality rate for single-center dialysis patients was 1.91%. The residence of COVID-19 patients was mainly concentrated in Qiaokou District (29.89%), Jianghan District (16.67%), and Hanyang District (15.56%), as illustrated in Figure 1.

Of the patients with COVID-19 (suspected + diagnosed), 40 (44.44%) were men and 50 (55.56%) were women, with an average age of 61.34 ± 12.59 years. There were 34 cases (37.78%) with primary glomerulonephritis, 16 cases (17.78%) with diabetic nephropathy, 24 cases (26.67%) with hypertensive renal damage, four cases (4.44%) with lupus nephritis, and 12 cases (13.33%) with other diseases [Table 1].

Among the primary clinical manifestations of COVID-19 cases, asymptomatic ones accounted for 26%. Cough was
the most common (36%) complaint in symptomatic patients, followed by fatigue (16%), dyspnea (16%), fever (13%), anorexia (4%), diarrhea (2%), and vomiting (1%). Of the patients undergoing MHD infected with COVID-19, most were classified into the common type, followed by the severe type, and the critical type [Figure 2].

**Hemodialysis characteristics**
A comparison of hemodialysis-related characteristics between the three groups showed that ultrafiltration volume, ultrafiltration rate, and duration of weekly hemodialysis in the diagnosed group were significantly lower than those in the other two groups (P < 0.05) [Table 2].

**Laboratory results**
The comparison in laboratory results between the three groups indicated that N%, N#, M#, and TCO₂ levels in the diagnosed group was significantly higher than those in the normal group but L% was significantly lower [Table 3].

**Imaging examination**
Of all suspected and diagnosed patients, 65 had positive pulmonary CT findings, including 12 (18.46%) patients with single lung involvement, 53 (81.54%) patients with both lung involvement, 10 (15.38%) with a single lesion, 55 (84.62%) with multiple lesions, 40 (61.54%) with patchy lesions, 23 (35.38%) with ground-glass opacities, and 2 (3.08%) patients with patchy ground-glass opacities [Figure 3].

**DISCUSSION**
This study was performed in a single center, focusing on all patients undergoing dialysis and patients with COVID-19

---

**Table 1: Comparison of general characteristics among normal, suspected, and coronavirus disease 2019 diagnosed patients undergoing maintenance hemodialysis**

| Characteristics          | Normal group (n=537) | Suspected group (n=24) | Diagnosed group (n=66) | χ²/F/Z | p    |
|--------------------------|----------------------|------------------------|------------------------|--------|------|
| Sex (male)               | 305 (56.80)          | 11 (45.83)             | 29 (43.94)             | 4.778  | 0.092|
| Age                      | 60.35±12.61          | 58.33±12.54            | 62.44±12.14            | 1.176  | 0.309|
| Hemodialysis (months)    | 62 (39.94)           | 68 (36.98)             | 57 (36.71)             | 0.605  | 0.739|
| Primary disease          |                      |                        |                        |        |      |
| Primary glomerulonephritis | 294 (54.75)         | 13 (4.0)                | 21(31.82)              | 19.675 | 0.007|
| Diabetic nephropathy     | 72 (13.41)           | 2 (8.33)                | 14 (21.21)             |        |      |
| Hypertensive renal damage | 91 (16.95)          | 4 (16.67)               | 20 (30.30)             |        |      |
| Lupus nephritis          | 11 (2.05)            | 0                      | 4 (6.06)               |        |      |
| Other diseases           | 69 (12.85)           | 5 (20.83)               | 7 (10.61)              |        |      |
Table 2: Comparison of hemodialysis-related characteristics among normal, suspected, and coronavirus disease 2019 diagnosed patients undergoing maintenance hemodialysis

| Characteristics | Normal group (n=537) | Suspected group (n=24) | Diagnosed group (n=66) | F/Z/χ² | P |
|-----------------|----------------------|------------------------|------------------------|--------|---|
| Duration of weekly hemodialysis (h/week) | 10.12±2.57 | 10.52±2.08 | 9.22±2.09 | 4.186 | 0.016 |
| Vascular access type | | | | | |
| AVF | 424 (79.0) | 18 (75.0) | 46 (69.7) | 3.037 | 0.219 |
| Non-AVF | 113 (21.0) | 6 (25.0) | 20 (30.3) | | |
| Dry weight (kg) | 59.58±12.61 | 62.74±17.07 | 59.03±11.20 | 0.744 | 0.476 |
| Ultrafiltration volume (kg) | 2.16±0.82 | 2.33±0.89 | 1.64±0.76 △▲ | 10.610 | <0.001 |
| Ultrafiltration rate | 0.79±0.27 | 0.83±0.33 | 0.61±0.28 △▲ | 8.648 | <0.001 |
| Dehydration ratio | 1.37±0.11 | 1.38±0.10 | 1.35±0.07 | 1.070 | 0.344 |
| SBP (mmHg) | 147.4±21.88 | 151.26±23.46 | 145.46±29.57 | 0.508 | 0.620 |
| DBP (mmHg) | 79.80±12.71 | 80.39±16.29 | 76.71±14.52 | 1.276 | 0.280 |

*Represents P < 0.05 compared with the normal group, △ P < 0.05 compared with the suspected group. AVF: Arteriovenous fistula, SBP: Systolic blood pressure, DBP: Diastolic blood pressure

Table 3: Comparison in laboratory indices between the three groups

| Index | Normal group (n=537) | Suspected group (n=24) | Diagnosed group (n=66) | F/Z/χ² | P |
|-------|----------------------|------------------------|------------------------|--------|---|
| WBC (10^9/L) | 6.06±2.69 | 6.37±1.81 | 6.50±3.35 | 0.751 | 0.472 |
| RBC (10^12/L) | 3.53±0.66 | 3.82±1.14 | 3.50±0.66 | 1.897 | 0.151 |
| Hemoglobin (g/L) | 103.02±17.41 | 99.08±18.95 | 101.29±17.54 | 0.812 | 0.445 |
| PLT (10^9/L) | 166.10±61.65 | 192.33±61.08 | 160.43±79.02 | 2.283 | 0.103 |
| N% (%) | 69.63±9.29 | 72.10±8.02 | 72.81±9.73 △ | 3.997 | 0.019 |
| N# (10^3/L) | 4.19±1.94 | 4.66±1.35 | 4.82±3.11 △ | 3.139 | 0.044 |
| L% (%) | 18.80±6.87 | 17.17±5.83 | 16.56±7.28 △ | 3.554 | 0.029 |
| L# (10^3/L) | 1.05±0.42 | 1.13±0.50 | 0.95±0.41 | 2.293 | 0.102 |
| M% (%) | 6.96±2.69 | 6.72±2.88 | 7.76±3.19 | 2.635 | 0.073 |
| M# (10^9/L) | 0.40±0.18 | 0.43±0.20 | 0.46±0.20 △ | 3.728 | 0.025 |
| CRP (mg/L) | 5.28 (3.23-21.75) | 6.52 (3.23-82.65) | 6.98 (3.23-34.80) | 0.735 | 0.693 |
| ESR (mm/h) | 25.00 (46.00-75.00) | 81.00 (55.50-102.00) | 53.50 (22.50-85.75) | 3.434 | 0.180 |
| GPT (U/L) | 9.00 (6.00-13.00) | 8.00 (6.00-14.00) | 10.00 (6.00-13.00) | 0.092 | 0.955 |
| GOT (U/L) | 14.00 (11.00-18.00) | 13.00 (10.00-17.00) | 13.00 (11.50-20.00) | 0.276 | 0.871 |
| TP (g/L) | 64.63±6.10 | 64.73±4.91 | 65.06±6.09 | 0.146 | 0.864 |
| ALB (g/L) | 38.71±3.87 | 37.32±6.72 | 38.54±4.38 | 1.304 | 0.272 |
| γ-GT (U/L) | 16.00 (12.00-29.00) | 19.00 (13.00-52.00) | 20.00 (14.00-32.00) | 4.248 | 0.120 |
| PCT (μg/L) | 0.40 (0.19-1.27) | 0.77 (0.26-5.43) | 0.59 (0.31-1.24) | 2.684 | 0.025 |
| LDH (U/L) | 183.17±59.12 | 169.92±40.45 | 184.60±51.96 | 0.344 | 0.709 |
| BUN (mmol/L) | 17.43±8.83 | 18.05±10.18 | 16.33±8.70 | 0.524 | 0.592 |
| Creatinine (μmol/L) | 710.17±337.12 | 667.83±355.32 | 694.65±321.22 | 0.223 | 0.800 |
| TCO2 (mmol/L) | 22.91±3.48 | 23.01±3.61 | 24.10±3.14 △ | 3.375 | 0.035 |
| UA (mmol/L) | 313.87±160.92 | 348.35±182.54 | 300.15±156.80 | 0.760 | 0.468 |
| K+ (mmol/L) | 4.54±0.87 | 4.47±1.11 | 4.52±0.89 | 0.094 | 0.910 |
| Ca2+ (mmol/L) | 2.15±0.27 | 2.10±0.20 | 2.16±0.28 | 0.503 | 0.605 |
| Phosphorus (mmol/L) | 1.67±0.55 | 1.78±0.79 | 1.66±0.59 | 0.461 | 0.631 |
| PTH (pg/mL) | 322.65 (159.05-322.65) | 295.80 (108.25-500.88) | 242.60 (117.83-465.35) | 5.841 | 0.054 |
| SF (μmol/L) | 12.55±7.84 | 11.17±3.82 | 8.16±4.29 | 1.622 | 0.201 |

*Indicates comparison with the normal group, P < 0.05. WBC: White blood cells, RBC: Red blood cells, PLT: Platelets, N%: Neutrophil ratio, N#: Neutrophil, L%: Lymphocyte ratio, L#: Lymphocyte, M%: Monocyte percentage, M#: Monocyte, GPT: Glutamic pyruvic transaminase, GOT: Glutamic oxalacetic transaminase, TP: Total protein, ALB: Albumin, γ-GT: γ-glutamyl transpeptidase, PCT: Procalcitonin, LDH: Lactate dehydrogenase, BUN: Blood urea nitrogen, TCO2: Total carbon dioxide, UA: Uric acid, PTH: Parathyroid hormone, CRP: C-reactive protein, ESR: Erythrocyte sedimentation rate, SF: Serum ferritin
undergoing MHD. The epidemiological and clinical data of 627 patients undergoing MHD were collected retrospectively. The results suggest that the COVID-19 infection rate and mortality rate of patients undergoing MHD are high, which deserves great attention.

The results of this study showed that the overall morbidity in our center was 10.53%, while the death rate was 18.18%, which was similar to some foreign research results. However, the mortality was higher than that of the single-center study in Jinyintan Hospital of Wuhan (11%) and significantly higher than the overall domestic case-fatality rate (2.3%). Reports indicated that the prevalence of COVID-19 in patients undergoing dialysis (1.72%) was significantly higher than in the general population (0.003%). The immune system of patients undergoing dialysis is impaired to varying degrees, which leads to a higher risk of infection and death from COVID-19. The average age of patients was greater than that of the patients not undergoing maintenance dialysis in the same study. Evidence demonstrated that older patients are more vulnerable to COVID-19 and tend to become more critically ill. Patients undergoing dialysis need to share the room with others, which increases the risk of additional infections. As a result, the prevalence and mortality of patients with COVID-19 undergoing MHD are higher.

Cough was the most common (36%) symptom in our study, followed by fatigue (16%) and dyspnea (16%), which were slightly different from the fever symptoms reported in other studies. However, it is hard to distinguish the symptoms of COVID-19 from uremia symptoms in patients undergoing dialysis. Besides, most of the patients undergoing MHD had no clinical manifestations, which was consistent with some previous reports, thus significantly increasing the difficulty of screening. The result also suggests that the common type was dominant in the patients undergoing MHD infected with COVID-19, followed by the severe and critical types. This is consistent with previous studies. Therefore, screening of patients in the hemodialysis room should be clinically strengthened.

This study showed that the duration of weekly hemodialysis, ultrafiltration rate, and ultrafiltration volume of patients in the diagnosed group were significantly lower than those in the other two groups, and thus might not guarantee adequate hemodialysis and may prevent timely removal of excess toxins and water from the body. This, in turn, may cause a series of complications such as water-sodium retention, electrolyte disorder, malnutrition, and increased death risk of patients. Therefore, during the epidemic, hemodialysis must be performed for as long as possible, and the ultrafiltration rate should be improved to ensure adequate hemodialysis and reduce carbon dioxide accumulation, so as to reduce the risk of infection.

Laboratory indicators in this study showed that L% in the diagnosed group was significantly lower than that in the normal group, which was consistent with similar studies. However, due to long-term dialysis, the immune system function is widely damaged; therefore, lymphocytopenia is common in patients undergoing dialysis, regardless of whether they are infected with COVID-19. Therefore, whether or not lymphocytopenia helps to identify COVID-19 in the early phase of infection needs further investigation. This study also revealed that N%, N#, and M# in the diagnosed group were significantly higher than those in the normal group. Studies have shown that mortality in patients with COVID-19 is associated with decreased lymphocytes and increased neutrophils; this may be one of the reasons for the high mortality rate of patients with COVID-19 in our center. The typical radiological pattern showed multifocal patchy peripheral consolidations in bilateral lungs. In the present study, lung CT of patients with COVID-19 more commonly showed multiple patchy shadows in both lungs. Chest CT scan has been suggested as a useful tool to screen the suspected cases of COVID-19 infection and discard false-negative cases. Thus, screening of lung CT should be performed for patients undergoing MHD in a timely manner, as well as early detection, isolation, and treatment.

This study has some limitations. First, this was a cross-sectional study, and thus further longitudinal investigations on the changes of the disease patterns are required. Second, the patients undergoing MHD who are diagnosed with COVID-19 must be transferred to designated hospitals for treatment under the government’s regulations; thus, the examination results were not complete. Besides, this was a single-center study with a relatively...
small sample size; therefore, the results need to be confirmed by future multi-center studies with a large sample size.

Financial support and sponsorship
This study was supported by the Scientific Research Project of Wuhan Municipal Health and Family Planning Commission (WG18C01).

Conflicts of interest
Fei Xiong is an Editorial Board Member of the journal. The article was subject to the journal’s standard procedures, with peer review handled independently of this member and his research group.

Ethics approval and consent to participate
This study was approved by the Ethics Committee of Wuhan First Hospital ([2020] No. 8). This study followed the guidelines of the Declaration of Helsinki and the consent was obtained from all parents.

REFERENCES
1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497‑506.
2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020;395:565‑74.
3. Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‑CoV, MERS‑CoV, and 2019‑nCoV. J Med Virol 2020;92:1902‑14.
4. The National Health Commission, the State Administration of Traditional Chinese Medicine. COVID‑19 diagnosis and treatment program (Trial Sixth Edition). Chin J Viral Dis 2020;10:81‑5.
5. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short‑term outcome of hemodialysis patients with SARS‑CoV‑2 infection. Kidney Int 2020;98:20‑6.
6. Goicoechea M, Sánchez Cámara LA, Macnás N, Muñoz de Morales A, Rojas ÁG, Bascuñana A, et al. COVID‑19: Clinical course and outcomes of 36 hemodialysis patients in Spain. Kidney Int 2020;98:27‑34.
7. Albalate M, Arribas P, Torres E, Cintra M, Alcázar R, Puerta M, et al. High prevalence of asymptomatic COVID‑19 in haemodialysis: Learning day by day in the first month of the COVID‑19 pandemic. Nefrologia (Engl Ed) 2020;40:279‑86.
8. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507‑13.
9. She J, Jiang J, Ye L, Hu L, Bai C, Song Y. 2019 novel coronavirus of pneumonia in Wuhan, China: Emerging attack and management strategies. Clin Transl Med 2020;9:19.
10. Kwan BC, Leung CB, Szeto CC, Wong VW, Cheng YL, Yu AW, et al. Severe acute respiratory syndrome in dialysis patients. J Am Soc Nephrol 2004;15:1883‑8.
11. Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end‑stage renal disease. Chest 2001;120:1883‑7.
12. Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. The Novel Coronavirus 2019 epidemic and kidneys. Kidney Int 2020;97:824‑8.
13. Basile C, Combe C, Pizzarelli F, Covic A, Davenport A, Kanbay M, et al. Recommendations for the prevention, mitigation and containment of the emerging SARS‑CoV‑2 (COVID‑19) pandemic in haemodialysis centres. Nephrol Dial Transplant 2020;35:737‑41.
14. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person‑to‑person transmission: A study of a family cluster. Lancet 2020;395:514‑23.
15. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‑19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395:1054‑62.
16. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical characteristics of 3062 COVID‑19 patients: A meta‑analysis. J Med Virol 2020;92:1902‑14.
17. Yoon SH, Lee KH, Kim JY, Lee YK, Ko H, Kim KH, et al. Chest radiographic and CT findings of the 2019 novel coronavirus disease (COVID‑19): Analysis of nine patients treated in Korea. Korean J Radiol 2020;21:494‑500.
18. Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, et al. Emerging 2019 novel coronavirus (2019‑nCoV) pneumonia. Radiology 2020;295:210‑7.
19. Li D, Wang D, Dong J, Wang N, Huang H, Xu H, et al. False‑negative results of real‑time reverse‑transcriptase polymerase chain reaction for severe acute respiratory syndrome coronavirus 2: Role of deep‑learning‑based CT diagnosis and insights from two cases. Korean J Radiol 2020;21:505‑8.